miR-346 directly targets Bcl-6 to promote Tfh cell differentiation in the pathogenesis of Graves’ disease, whereas Bcl-6 binds to the miR-31 promoter to repress its transcription, leading to the release of CD40L and SAP, which contribute to Tfh function. Here, BCL6 is linked to Graves disease.